Our data indicated that patients with GPA-associated CDI with PR3-ANCA positivity had higher BVAS scores and predicted risk of relapse even after treatment, which was also supported by the RAVE trial (42). This evidence concerns the gene PRTN3 and clostridium difficile infection.